Tower Research Capital LLC (Trc) Protagonist Therapeutics, Inc Transaction History
Tower Research Capital LLC (Trc)
- $4.87 Billion
- Q4 2024
A detailed history of Tower Research Capital LLC (Trc) transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 7,369 shares of PTGX stock, worth $267,789. This represents 0.01% of its overall portfolio holdings.
Number of Shares
7,369
Previous 360
1946.94%
Holding current value
$267,789
Previous $16,000
1675.0%
% of portfolio
0.01%
Previous 0.0%
Shares
30 transactions
Others Institutions Holding PTGX
# of Institutions
254Shares Held
58.9MCall Options Held
226KPut Options Held
218K-
Farallon Capital Management LLC San Francisco, CA5.93MShares$215 Million1.22% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$209 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.5MShares$200 Million3.46% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.22MShares$153 Million0.0% of portfolio
-
State Street Corp Boston, MA3.33MShares$121 Million0.01% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $1.78B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...